1. Home
  2. EIC vs NKTR Comparison

EIC vs NKTR Comparison

Compare EIC & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EIC

Eagle Point Income Company Inc.

N/A

Current Price

$9.63

Market Cap

228.8M

Sector

Finance

ML Signal

N/A

Logo Nektar Therapeutics

NKTR

Nektar Therapeutics

N/A

Current Price

$70.66

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EIC
NKTR
Founded
N/A
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
228.8M
2.2B
IPO Year
2018
1996

Fundamental Metrics

Financial Performance
Metric
EIC
NKTR
Price
$9.63
$70.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$12.63
$146.67
AVG Volume (30 Days)
81.4K
487.3K
Earning Date
05-27-2026
05-07-2026
Dividend Yield
13.25%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$307,711,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.08
N/A
Revenue Growth
N/A
86.00
52 Week Low
$9.17
$33.40
52 Week High
$13.55
$109.00

Technical Indicators

Market Signals
Indicator
EIC
NKTR
Relative Strength Index (RSI) 39.63 36.65
Support Level $9.33 $67.11
Resistance Level $10.14 $76.63
Average True Range (ATR) 0.11 2.73
MACD -0.03 -0.90
Stochastic Oscillator 32.08 11.79

Price Performance

Historical Comparison
EIC
NKTR

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Share on Social Networks: